---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-21-022964"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2021-09-17T23:59:59+00:00"
generated_at: "2026-06-29T03:06:19.103732+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Enveric completes MagicMed acquisition; issues 9.95M shares (~31.7% ownership)

## Summary
- Enveric issued 9,951,237 shares to MagicMed shareholders, representing ~31.7% of combined company.
- Enveric received ~$4 million CAD cash from MagicMed treasury at closing.
- Dr. Joseph Tucker (ex-MagicMed CEO) appointed CEO of Enveric; David Johnson becomes Executive Chairman.
- Dr. Peter Facchini appointed Chief Scientific Officer; Dr. Jillian Hagel appointed Chief Technology Officer.
- Board expanded from 5 to 7; Tucker and Brad Thompson joined as directors.

## SEC filing metadata
- accession: 0001493152-21-022964
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2021-09-17T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-21-022964
- JSON: https://secwatch.observer/filing/0001493152-21-022964.json
- Plain text: https://secwatch.observer/filing/0001493152-21-022964.txt

## Key facts
- Executive change
  Dr. Jillian Hagel was appointed as Chief Technology Officer at Enveric Biosciences, Inc..
  - Action: appointed
  - Role: Chief Technology Officer
  source text: the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm
- Executive change
  Dr. Joseph Tucker was appointed as Director at Enveric Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: the Company appointed each of (i) Dr. Joseph Tucker, who served as president and chief executive officer, and as a director, of MagicMed immediately prior to the Effective Time and (ii) Brad Thompson, who served as a director of MagicMed immediately prior to the Effective Time, to the Company’s board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm
- Executive change
  David Johnson changed role as Executive Chairman at Enveric Biosciences, Inc..
  - Action: assigned
  - Role: Executive Chairman
  source text: assigned David Johnson, 63, the title of Executive Chairman of the Company, and removed the title of Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm
- Executive change
  Brad Thompson was appointed as Director at Enveric Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: the Company appointed each of (i) Dr. Joseph Tucker, who served as president and chief executive officer, and as a director, of MagicMed immediately prior to the Effective Time and (ii) Brad Thompson, who served as a director of MagicMed immediately prior to the Effective Time, to the Company’s board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm
- Executive change
  Dr. Peter Facchini was appointed as Chief Scientific Officer at Enveric Biosciences, Inc..
  - Action: appointed
  - Role: Chief Scientific Officer
  source text: the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm
- Executive change
  Dr. Joseph Tucker was appointed as Chief Executive Officer at Enveric Biosciences, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the Company appointed each of (i) Dr. Tucker, 53, (ii) Dr. Peter Facchini, 58 and (iii) Dr. Jillian Hagel, 43, to be Chief Executive Officer, Chief Scientific Officer and Chief Technology Officer, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315221022964/0001493152-21-022964-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.